Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.50
Bid: 297.50
Ask: 300.00
Change: -6.00 (-1.98%)
Spread: 2.50 (0.84%)
Open: 313.00
High: 313.50
Low: 296.50
Prev. Close: 302.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Shares

1 Feb 2008 10:40

Oxford Biomedica PLC01 February 2008 For immediate release 1 February 2008 Oxford BioMedica Plc Notifications of Major Interests in Shares TR-1: Notifications of Major Interests in Shares 1. Identity of the issuer or the underlying issuer ofexisting shares to which voting rights are attached: Oxford BioMedica Plc 2. Reason for notification (yes/no) Yes An acquisition or disposal of voting rights An acquisition or disposal of financial instruments which may result in the acquisitionof shares already issued to which voting rights are attached An event changing the breakdown of voting rights Other (please specify):______________ 3. Full name of person(s) subject to notification Legal & General Group Plc (L&G)obligation: Legal & General Assurance (Pensions Management) Limited (PMC)4. Full name of shareholder(s) (if different from3): 5. Date of transaction (and date on which the 30 January 2008threshold is crossed or reached if different): 6. Date on which issuer notified: 31 January 2008 7. Threshold(s) that is/are crossed or reached: 3% to 4% 8: Notified DetailsA: Voting rights attached to shares Class/type of Situation previous to the Resulting situation after the triggering transactionshares triggering transaction If possible useISIN code Number of Number of Number of Number of voting rights Percentage of voting shares voting shares rights rights Direct Indirect Direct IndirectGB0006648157 16,729,883 16,729,883 22,476,084 22,476,084 4.18% B: Financial Instruments Resulting situation after the triggering transaction Type of financial Expiration date Exercise/ conversion No. of voting rights Percentage of votinginstrument period/date that may be acquired rights (if the instrument exercised/converted) Total (A+B) Number of voting rights Percentage of voting rights22,476,084 4.18% 9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectivelyheld, if applicable:Legal & General Group Plc (Direct and Indirect) (Group) Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) Legal & General Investment Management Limited (Indirect) (LGIM) Proxy Voting:10. Name of proxy holder: 11. Number of voting rights proxy holder willcease to hold: 12. Date on which proxy holder will cease to holdvoting rights: 13. Additional information: 14 Contact name: Andrew Wood 15. Contact telephone name: 01865 783000 Registered Holder Holding % Legal & General Group PLC (Direct and Indirect) (Group) 22,476,084 4.18% Legal & General Assurance Society Limited Legal & General Pensions Limited Legal & General Assurance (Pensions Management) Limited Legal & General Investment Management (Holdings) Limited (Direct) 20,153,912 3.75% Legal & General Assurance (Pensions Management) Limited Legal & General Insurance Holdings Limited (Direct) 20,153,912 3.75% Legal & General Assurance (Pensions Management) Limited Legal & General Assurance (Pensions Management) Limited 20,153,912 3.75% Legal & General Assurance Society Limited Legal & General Pensions Limited This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Sep 20237:00 amRNSInterim results
1st Sep 20237:00 amRNSTotal Voting Rights
22nd Aug 20237:00 amRNSExpanded agreement with Cabaletta Bio
14th Aug 20237:00 amRNSNotice of Interim Results
1st Aug 20237:00 amRNSTotal Voting Rights
3rd Jul 20234:31 pmRNSPDMR Dealings
3rd Jul 20237:00 amRNSOxford Biomedica PLC - Block Listing Return
3rd Jul 20237:00 amRNSTotal Voting Rights
23rd Jun 20235:32 pmRNSResult of AGM
6th Jun 20233:59 pmRNSTotal Voting Rights
15th May 20237:00 amRNSOxford Biomedica launches TetraVecta system
10th May 20237:00 amRNSBlock listing Application
5th May 20237:00 amRNS2023 AGM Notification
2nd May 20237:00 amRNSTotal Voting Rights
28th Apr 20237:59 amRNS2022 Annual Report and Accounts
26th Apr 20237:00 amRNSBoard Appointment
25th Apr 20237:00 amRNSPreliminary results for the year ended 31 Dec 2022
19th Apr 20236:26 pmRNS2022 Preliminary results revised date
3rd Apr 20231:19 pmRNSTotal Voting Rights
30th Mar 20237:00 amRNSNotice of Preliminary Results
13th Mar 202311:33 amRNSOXB confirms no exposure to SVB receivership
1st Mar 202311:16 amRNSTotal Voting Rights
20th Feb 20237:00 amRNSDr Frank Mathias to join as new CEO on 27 March
1st Feb 202310:18 amRNSTotal Voting Rights
27th Jan 20237:00 amRNSBoard Change
3rd Jan 20235:19 pmRNSBlock listing return
3rd Jan 202311:28 amRNSTotal Voting Rights
21st Dec 202212:00 pmRNSOxford Biomedica to Present at J.P Morgan
14th Dec 20227:00 amRNSOxford Biomedica Solutions forms new partnerships
22nd Nov 20227:00 amRNSOxford Biomedica Appoints Frank Mathias as CEO
15th Nov 20222:35 pmRNSHolding(s) in Company
14th Nov 20227:00 amRNSSale and leaseback of Windrush Court facility
1st Nov 20229:14 amRNSTotal Voting Rights
14th Oct 20222:28 pmRNSPDMR Dealings
12th Oct 20227:00 amRNSPDMR Dealings
12th Oct 20227:00 amRNSPDMR Dealings
7th Oct 20221:16 pmRNSPDMR Dealing Amendment
7th Oct 202212:28 pmRNSPDMR Dealing
7th Oct 20227:00 amRNSAmendment of Short-Term Loan Facility
3rd Oct 20229:34 amRNSTotal Voting Rights
15th Sep 20227:00 amRNSInterim Results
14th Sep 20227:00 amRNSOxford Biomedica Solutions signs new partner
7th Sep 20227:00 amRNSLicence & Supply Agreement with New Partner
1st Sep 20229:51 amRNSTotal Voting Rights
25th Aug 20227:00 amRNSNotice of Interim Results
16th Aug 20227:00 amRNSOxford Biomedica Notes Homology Q2 Report
1st Aug 20229:42 amRNSTotal Voting Rights
27th Jul 20227:00 amRNSAppointment of Joint Corporate Broker
26th Jul 20227:00 amRNSLicence & Supply Agreement with New Partner
26th Jul 20227:00 amRNSNew Project with Orchard Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.